Efficacy of tranexamic acid in reducing perioperative blood loss and transfusion requirements following limb-salvage surgery for bone tumors: A randomized controlled trial
Journal of Orthopaedic Surgery · 2026-09 · 34 (3)
DOI: 10.1177/10225536261507391 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Orthopaedic Surgery, online erschienen am 06.11.2026. Verfasst von Muhammad Bilal Shafiq und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan. Hauptthemen laut MEDLINE: Antifibrinolytic Agents, Blood Loss, Surgical, Blood Transfusion, Bone Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Imperial College London.
Abstract (Originalsprache)
Background
Limb salvage surgery with endoprosthetic reconstruction for malignant bone tumors is frequently associated with substantial perioperative blood loss and high transfusion requirements. Although tranexamic acid (TXA) has demonstrated efficacy in reducing blood loss in total joint arthroplasty, high-level evidence supporting its use in orthopaedic oncology remains limited.
Methods
We conducted a prospective, double-blind, randomized controlled trial between April 2023 and September 2025. Thirty-six patients undergoing tumor resection and endoprosthetic reconstruction of the femur(Proximal/distal/total), proximal tibia, or proximal humerus were randomized to receive either intravenous TXA (15 mg/kg at induction; n = 18) or placebo (n = 18). The primary outcome was calculated total blood loss at 72 hours using the hemoglobin balance method. Secondary outcomes included transfusion requirements, postoperative hemoglobin concentration, drain output, hospital stay, wound complications, and thromboembolic events. All patients completed a minimum follow-up of six weeks.
Results
Mean calculated blood loss at 72 hours was lower in the TXA group than in the control group (995 ± 324 mL versus 1708 ± 508 mL; mean difference 713 mL; p < 0.001). Patients receiving TXA required fewer packed red blood cell transfusions (1.1 ± 0.7 versus 1.7 ± 0.7 units; mean difference 0.6 units; p = 0.01). Postoperative hemoglobin concentration was higher in the TXA group (9.3 ± 1.1 versus 8.7 ± 0.9 g/dL), although this difference was not significant (p = 0.073). No differences were observed in drain output, wound complications, or hospital stay. No symptomatic deep vein thrombosis or pulmonary embolism occurred in either group.
Conclusion
In this single-center randomized controlled trial, tranexamic acid was associated with reduced calculated total blood loss at 72 hours. However, the relatively small sample size limits conclusions regarding uncommon adverse events. Larger multicenter randomized controlled trials are warranted to confirm these findings and further evaluate safety across diverse orthopaedic oncology settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan.
ORCID-Profile: Muhammad Bilal Shafiq
Förderung
- Imperial College London
Zitieren
APA
Shafiq, M. B., Rafi, I., Ali, S., Shoaib, A., & Rao, A. M. (2026). Efficacy of tranexamic acid in reducing perioperative blood loss and transfusion requirements following limb-salvage surgery for bone tumors: A randomized controlled trial. Journal of Orthopaedic Surgery, 34(3). https://doi.org/10.1177/10225536261507391
Vancouver
Shafiq MB, Rafi I, Ali S, Shoaib A, Rao AM. Efficacy of tranexamic acid in reducing perioperative blood loss and transfusion requirements following limb-salvage surgery for bone tumors: A randomized controlled trial. Journal of Orthopaedic Surgery. 2026;34(3). doi:10.1177/10225536261507391
BibTeX
@article{Shafiq2026,
author = {Shafiq, Muhammad Bilal and Rafi, Ilyas and Ali, Sajid and Shoaib, Ahmed and Rao, Ahsan Mumtaz},
title = {Efficacy of tranexamic acid in reducing perioperative blood loss and transfusion requirements following limb-salvage surgery for bone tumors: A randomized controlled trial},
journal = {Journal of Orthopaedic Surgery},
year = {2026},
volume = {34},
number = {3},
doi = {10.1177/10225536261507391}
}
EUVIMED